कोशिश गोल्ड - मुक्त
Setting Bigger Targets For Next-Gen Vaccines
Bio Spectrum
|July 2024
New vaccine platform technologies could dramatically shorten the period from research to development, clinical trials, and vaccination. Reimagining R&D approaches in vaccine design and vaccine immunology may hold the key to significantly elevate the health impact of vaccines.
Experts worldwide are adopting novel research approaches in the molecular design of vaccines, and vaccine technology platforms. India is seeing increasing interdisciplinary research, and a rise in cutting-edge technological interventions in fundamental and translational research. The time is ripe for boosting out-of-the-box R&D approaches in vaccinology. Let's explore further.
The National Institute for Allergy and Infectious Diseases (NIAID), one of the 27 institutes and centres that make up the National Institutes of Health (NIH) of the US, referred to next-generation vaccines as those with enhanced breadth of protection to variants, improved durability, and enhanced ability to block infection/transmission relative to currently approved vaccines. The Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership working to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic, describes vaccine technology platforms as technologies that are essential for rapid responses to emerging viral threats.
Essentially, vaccine platform technologies are systems that use the same basic components as a backbone but can be adapted for use against different pathogens by inserting new genetic or protein sequences. Rational vaccine design, developed using suitable vaccine technology platforms, could thus present significant advantages in immunisation.
Creating such an unprecedented disease agnostic vaccine technology platform can empower the world to be ready for future pandemics. Studies have shown that next-generation vaccines can enable a higher spectrum of protection against multiple variants, increased durability, and minimal safety concerns due to side effects while increasing their immunogenicity.
Each vaccine's utility or efficiency is determined by its formulation, adjuvants, and mode of action.
यह कहानी Bio Spectrum के July 2024 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
Bio Spectrum से और कहानियाँ
Bio Spectrum
Molbio announces collaboration with UE LifeSciences to expand iBreastExam globally
Molbio Diagnostics, a Goa-based point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies, and UE LifeSciences, a Philadelphia-based innovator engaged in the business of developing and manufacturing health technology solutions, with a primary focus on enabling early cancer detection technologies, have announced an exclusive collaboration, seeking to make early breast cancer detection accessible to millions of women in over 50 countries across the developing world.
1 min
November 2025
Bio Spectrum
CRO Reforms: Tilting Scale towards Accelerated Growth & Transparency
India's clinical research ecosystem is undergoing a major transformation, driven by a wave of regulatory reforms and rapid market expansion.
10 mins
November 2025
Bio Spectrum
When Spectra Speak: Letting AI Read the Fine Print of Biologics
Biologic characterisation has historically relied heavily on spectroscopy, which transforms chemical complexity into comprehensible fingerprints. Through the careful use of AI, supported by strict data procedures and scientific supervision, these fingerprints may be read more quickly & thoroughly.
5 mins
November 2025
Bio Spectrum
Working on our supply chain to set benchmarks in quality and further enhance India's position as a trusted clinical research supplier on a global scale
Abdos Lifesciences, which is committed to enabling science to thrive by delivering precision-engineered, high-performance laboratory consumables and instruments that meet the highest global standards, manufactures over 400 products across 12+ categories in automated cleanroom environments certified under ISO and CE-IVDR standards, ensuring sterility, traceability, and consistency crucial for decentralised and global clinical trials. Each product is barcoded, tamper-proof, and supported by easily accessible documentation such as Certificates of Analysis (COA), Technical Data Sheets (TDS). With a presence in more than 90 countries, Abdos Lifesciences ensures researchers worldwide receive reliable products and dedicated support, empowering science to advance seamlessly across borders and timelines. In an interview with BioSpectrum India Shrey Agarwal, CEO & Director, Abdos Lifesciences spoke to many issues including how the company is ensuring compliance with evolving global standards for products used in regulated clinical environments. Edited excerpts;
4 mins
November 2025
Bio Spectrum
Gene Solutions and AMPATH launch advanced genomics laboratory in Hyderabad
Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnostic services in India, to open a new advanced genomics laboratory in Hyderabad.
1 min
November 2025
Bio Spectrum
Patient Consent - How is it different under medical ethics and data protection?
In the ethical and legal framework of medicine and law, consent has always existed. Within healthcare, it signifies the individual's right to be informed and to choose. However, in the digital era, consent assumes a broader function; it becomes the foundation for lawful processing of personal data. For the pharma and clinical-research sectors, this distinction carries significant implications. The Digital Personal Data Protection Act, 2023 (DPDPA), has redefined how personal and health-related data must be managed. This article explores why consent under data-protection law differs from medical consent, drawing lessons from the irregularities uncovered in the Ahmedabad clinical trials, and outlines the emerging compliance responsibilities under the DPDPA.
3 mins
November 2025
Bio Spectrum
We aim to make bio-based industries a key pillar of the state's GSDP by 2030: Kerala CM
Kerala recently set the spotlight on its growing life sciences ecosystem with Bio Connect 3.0 – International Life Sciences Conclave & Expo, held on October 9 & 10, 2025, in Thiruvananthapuram.
3 mins
November 2025
Bio Spectrum
DBT inks pact with Uttar Pradesh to boost biotech, pharma and medtech innovation
An official Memorandum of Understanding (MoU) has been signed between the Department of Biotechnology (DBT), Government of India and the Government of Uttar Pradesh.
1 min
November 2025
Bio Spectrum
Abbott launches world's first dual-chamber leadless pacemaker system in India
Abbott, a global healthcare company, has announced the launch of AVEIR dual chamber (DR) leadless pacemaker system - the first of its kind in the world.
1 min
November 2025
Bio Spectrum
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
Delhi-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
November 2025
Listen
Translate
Change font size
